why choose us

First received: November 23, 2022

Clinical Trial: A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults

Study Status: Completed

Recruit Status: RECRUITING

Condition: HIV

Study Type: INTERVENTIONAL


Official Title: VRC 615: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB-0115-AB (VRC01.23LS), Administered Intravenously or Subcutaneously t

Brief Summary: Background:HIV causes AIDS, a serious disease that can lead to fatal infections.HIV infection can be controlled but not cured, nor is there a vaccine to prevent it.Antibodies may offer a promising new way to prevent HIV infection.Antibodies are proteins that are naturally made by the body to fight germs.One antibody (VRC01.23LS)has been tested in the lab and was found to block HIV-like viruses.Researchers want to find out if it is safe to inject VRC01.23LSinto people.Objective:To test the safety of VRC01.23LS in…

Read more